LifeMD, Inc.

Overview

Compare with SBC Medical Group Holdings Inc, Airsculpt Technologies, Inc. or Starling Oncology, Inc., or pick any stock.

• TickerLFMD on Nasdaq¹
• IndustryServices-Offices & Clinics of Doctors of Medicine¹
• HeadquartersNew York, New York¹
• Incorporated inDE²
• Business address236 Fifth Avenue, Suite 400, New York, Ny 10001²
• Filer categoryAccelerated filer²

See how the biggest companies compare on our leaderboards

LifeMD brand is our flagship virtual primary care and specialty platform, having served over 679,000 customers and patients to date.⁴ From its latest annual report

Corporate structure

LifeMD, Inc. sits at the top of its group. 4 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What LifeMD, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

The Company leases office space domestically under operating leases including: (1) the Company’s headquarters in New York, New York for which the lease expires in 2028, (2) a marketing and sales center in Huntington Beach, California for which the lease expires in 2027, (3) a patient care center in Greenville, South Carolina for which the lease expires in 2032, with an additional five year option to extend, for which the Company expects to utilize, and (4) a warehouse and pharmacy operations center in Lancaster, Pennsylvania for which the lease expires in 2029, with an additional five year option to extend, for which the Company expects to utilize.

Leased premises range from approximately 1,000 to 23,000 square feet with monthly rents ranging from approximately $1,800 per month to approximately $60,000 per month.

Item 2 of the 10-K filed Mar 10, 2026.⁴

Leadership

Who has led LifeMD, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJustin Schreiber Mar 28, 2018 to now¹³
• ChairJustin Schreiber Mar 20, 2025 to now¹⁴
• PresidentAlexander Mironov Sep 10, 2021 to Aug 1, 2023¹⁵
• PresidentJustin Schreiber Oct 27, 2017 to Feb 12, 2018¹⁶
• Chief financial officerAtul Kavthekar Apr 1, 2026 to now¹⁷
• Chief financial officerMarc David Benathen Feb 10, 2021 to Apr 1, 2026¹⁸
• Chief financial officerDagnery Juan Manuel Pineiro Apr 10, 2019 to Apr 10, 2019¹⁹
• Chief financial officerRobert L. Kalkstein Nov 13, 2017 to Mar 4, 2019²⁰
• Chief operating officerShayna Webb Dray Jul 31, 2025 to now²¹
• Chief operating officerBrad Michael Roberts Feb 3, 2021 to Jun 15, 2023²²
• Chief operating officerStefan Galluppi Nov 22, 2017 to Sep 24, 2020²³

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• LifeMD Pharmacy Holdings 1, LLC Delaware³
• LifeMD Pharmacy Holdings, LLC Delaware³
• LifeMD Pharmacy Services, LLC Delaware³
• LifeMD, Inc. Delaware³

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• CONVERSION LABS, INC.Jun 27, 2018 to Feb 22, 2021²
• Immudyne, Inc.May 17, 2012 to Jun 19, 2018²

Timeline

1. Sep 15, 20268-K Regulation FD disclosure⁵²
2. Aug 5, 20268-K Results of operations; Regulation FD disclosure⁵³
3. Jun 22, 20268-K Regulation FD disclosure⁵⁴
4. May 6, 20268-K Results of operations; Regulation FD disclosure⁵⁵
5. Mar 18, 20268-K Executive or director change; Other events⁵⁶
6. Mar 9, 20268-K Results of operations; Regulation FD disclosure⁵⁷
7. Jan 6, 20268-K Entered a material agreement; New debt or obligation; Regulation FD disclosure⁵⁸
8. Nov 17, 20258-K Results of operations⁵⁹
9. Nov 5, 20258-K Regulation FD disclosure⁶⁰
10. Nov 4, 20258-K Entered a material agreement; Completed an acquisition or sale; Regulation FD disclosure⁶¹
11. Aug 21, 20258-K Change of auditor⁶²
12. Aug 5, 20258-K Results of operations⁶³
13. Mar 28, 2018New chief executive Justin Schreiber becomes CEO¹³

Calendar

Coming up

1. Nov 16, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.10) a share, on Nov 17, 2025.⁶⁴

When it reported results

1. Aug 5, 2026Reported quarterly or annual results⁵³
2. May 6, 2026Reported quarterly or annual results⁵⁵
3. Mar 9, 2026Reported quarterly or annual results⁵⁷
4. Nov 17, 2025Reported quarterly or annual results⁵⁹
5. Aug 5, 2025Reported quarterly or annual results⁶³
6. May 6, 2025Reported quarterly or annual results⁶⁵
7. Mar 10, 2025Reported quarterly or annual results⁶⁶
8. Jan 19, 2022Reported quarterly or annual results⁶⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

263 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 129 insider forms, 7 large holders, 59 other. The latest 20:

1. Oct 7, 2026SCHEDULE 13G/A EDGAR
2. Sep 25, 2026S-8 EDGAR
3. Sep 15, 20268-K EDGAR
4. Aug 18, 20264 EDGAR
5. Aug 18, 20264 EDGAR
6. Aug 13, 20264 EDGAR
7. Aug 13, 20264/A EDGAR
8. Aug 13, 20264 EDGAR
9. Aug 13, 20264 EDGAR
10. Aug 5, 202610-Q EDGAR
11. Aug 5, 20268-K EDGAR
12. Jul 8, 2026SCHEDULE 13G EDGAR
13. Jun 22, 20268-K EDGAR
14. Jun 3, 20264 EDGAR
15. Jun 3, 20263 EDGAR
16. May 13, 20264 EDGAR
17. May 6, 202610-Q EDGAR
18. May 6, 20268-K EDGAR
19. Apr 30, 2026ARS EDGAR
20. Apr 30, 2026DEFA14A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

46 open-market trades by officers, directors and large owners since October 2021: 30 buys and 16 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Federated HermesSCHEDULE 13G/A, 2 filings Jul 8, 2026 to Oct 7, 2026⁶⁸
• Divisadero Street Capital Management, LPSC 13G/A, 3 filings Oct 6, 2023 to Nov 14, 2024⁶⁹
• BlackRockSC 13G, 2 filings Oct 24, 2024 to Nov 8, 2024⁷⁰

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How LifeMD, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARLifeMD, Inc.¹
• CIK0000948320
• Employer ID (EIN)76-0238453⁴
• Filer statusAccelerated filer not an emerging growth company; a smaller reporting company; a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)8011 Services-Offices & Clinics of Doctors of Medicine¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address236 Fifth Avenue, Suite 400, New York, NY 10001¹
• Phone(866) 351-5907¹
• Shares outstanding48,200,837 as of Aug 4, 2026¹²
• Public float$512.5M as of Jun 30, 2025⁴
• AuditorPricewaterhouseCoopers LLP, New York, New York PCAOB ID 238; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceMay 17, 2012¹
• Filings578 in all: 4 (181), 8-K (139), 10-Q (41), 3 (36), UPLOAD (16), 10-K (14), CORRESP (13), EFFECT (10)¹
  All 43 form types

  DEF 14A (9), DEFA14A (9), 144 (7), 424B3 (7), S-1/A (7), 424B5 (6), S-8 (6), SC 13G (6), 3/A (5), 4/A (5), D (5), 8-K/A (4), ARS (4), NT 10-Q (4), PRE 14A (4), S-1 (4), S-3 (4), S-3/A (4), 10-Q/A (3), 5 (3), SC 13D (3), 8-A12B (2), CERT (2), POS AM (2), PRER14A (2), SC 13G/A (2), 8-A12G (1), CT ORDER (1), D/A (1), DEFR14A (1), FWP (1), NT 10-K (1), SC 13D/A (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

• Latest filingsAnnual report (10-K) Mar 10, 2026
  Quarterly report (10-Q) Aug 5, 2026
  Proxy statement (DEF 14A) Apr 30, 2026
  Latest 8-K (8-K) Sep 15, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 10, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks LifeMD, Inc. names in Item 1A of its 10-K filed Mar 10, 2026: 45 risks under these headings, as written.⁴

• These disclosures reflect our beliefs and opinions as to risk factors that could materially and adversely affect the Company and its securities in the future. References to past events are provided by way of example only and are not intended to be a complete listing or a representation as to whether or not any other events have occurred in the past or their likelihood of occurring in the future.
• Risks Related to our Business and Industry
• We have generated net losses, we anticipate increasing expenses in the future, we have not yet achieved profitability, and we may not be able to achieve or maintain profitability.
• Our limited operating history and evolving business make it difficult to evaluate our current business and future prospects and increases the risk of your investment.
• The telehealth market is immature and volatile, and if it does not develop, if it develops more slowly than we expect, if it encounters negative publicity, or if our solution does not drive customer engagement, the growth of our business will be harmed.
• If we are unable to expand the scope of our offerings, including the number and type of products and services that we offer, the number and quality of healthcare providers serving our customers, and the number and types of conditions capable of being treated through our platform, our business, financial condition, and results of operations may be materially and adversely affected.
• We are expanding the use of AI in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability, and adversely affect our results of operations.
• If we are unable to successfully market to new customers and retain existing customers, or if evolving privacy, healthcare, or other laws prevent or limit our marketing activities, our business, financial condition, and results of operations could be harmed.
• Our revenue growth depends on consumers’ willingness to adopt our products, and the failure of our offerings to achieve and maintain market acceptance could result in us achieving revenue below our expectations, which could cause our business, financial condition, and results of operation to be materially and adversely affected.
• The market for our model and services is new, rapidly evolving, and increasingly competitive, as the healthcare industry in the U.S. is undergoing significant structural change and consolidation, which makes it difficult to forecast demand for our solutions.
• Competitive platforms or other technological breakthroughs for the monitoring, treatment, or prevention of medical conditions may adversely affect demand for our offerings.
• We operate in highly competitive markets and face competition from large, well-established healthcare providers and more traditional retailers and pharmaceutical providers with significant resources, and, as a result, we may not be able to compete effectively.

Legal proceedings

We may become involved in various lawsuits and legal proceedings arising in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may have an adverse effect on our business, financial condition or operating results. Future litigation may be necessary to defend ourselves and our customers by determining the scope, enforceability and validity of third-party proprietary rights or to establish our proprietary rights. For additional information on pending legal proceedings see Note 12—Commitments and Contingencies to our consolidated financial statements included in this report.

The opening of Item 3, Legal Proceedings.⁴